Renalytix Plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more
Renalytix Plc (RNLXY) - Total Liabilities
Latest total liabilities as of December 2024: $12.81 Million USD
Based on the latest financial reports, Renalytix Plc (RNLXY) has total liabilities worth $12.81 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Renalytix Plc - Total Liabilities Trend (2021–2025)
This chart illustrates how Renalytix Plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Renalytix Plc Competitors by Total Liabilities
The table below lists competitors of Renalytix Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nivika Fastigheter AB Series B
ST:NIVI-B
|
Sweden | Skr8.11 Billion |
|
Phoenix Asia Holdings Limited Ordinary Shares
NASDAQ:PHOE
|
USA | $2.26 Million |
|
Rani Therapeutics Holdings Inc
NASDAQ:RANI
|
USA | $22.11 Million |
|
Kudelski S.A.
LSE:0QNQ
|
UK | £228.06 Million |
|
OPTGF
PINK:OPTGF
|
USA | $148.72 Billion |
|
Unggul Indah Cahaya Tbk
JK:UNIC
|
Indonesia | Rp48.28 Million |
|
Keding Enterprises Co Ltd
TW:6655
|
Taiwan | NT$6.22 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down Renalytix Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Renalytix Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Renalytix Plc (2021–2025)
The table below shows the annual total liabilities of Renalytix Plc from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $13.10 Million | -17.22% |
| 2024-06-30 | $15.83 Million | -33.12% |
| 2023-06-30 | $23.66 Million | +21.61% |
| 2022-06-30 | $19.46 Million | +160.27% |
| 2021-06-30 | $7.48 Million | -- |